Needham Reiterates Buy on Praxis Precision Medicine, Maintains $145 Price Target
Portfolio Pulse from Benzinga Newsdesk
Needham analyst Ami Fadia has reiterated a Buy rating on Praxis Precision Medicine (NASDAQ:PRAX) and maintained a $145 price target.
August 12, 2024 | 9:29 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Needham analyst Ami Fadia has reiterated a Buy rating on Praxis Precision Medicine (NASDAQ:PRAX) and maintained a $145 price target.
The reiteration of a Buy rating and the maintenance of a high price target by a reputable analyst can boost investor confidence and potentially drive the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100